These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35483627)

  • 21. A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
    Mack I; Schwille-Kiuntke J; Mazurak N; Niesler B; Zimmermann K; Mönnikes H; Enck P
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1039-1047.e9. PubMed ID: 34214682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial.
    Kerckhove N; Scanzi J; Pereira B; Ardid D; Dapoigny M
    BMJ Open; 2017 Jul; 7(7):e015380. PubMed ID: 28720615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials.
    Liang SB; Cao HJ; Kong LY; Wei JL; Robinson N; Yang SH; Zhu SJ; Li YQ; Fei YT; Han M; Liu JP
    Front Pharmacol; 2022; 13():904657. PubMed ID: 36091782
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial.
    Zheng Y; Ching J; Cheng CW; Lam WC; Chan KL; Zhang X; Lam PY; Wu XY; Zhong LLD; Cao PH; Lo CW; Cheong PK; Lin Z; Koh M; Wu J; Bian ZX
    Chin Med; 2021 Nov; 16(1):117. PubMed ID: 34774080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study.
    Faghih Dinevari M; Jafarzadeh F; Jabbaripour Sarmadian A; Abbasian S; Nikniaz Z; Riazi A
    BMC Gastroenterol; 2023 Apr; 23(1):135. PubMed ID: 37098505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial.
    Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY
    BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY; Li M; Li YY; Li LX; Zhai WZ; Wang P; Yang XX; Gu X; Song LJ; Li Z; Zuo XL; Li YQ
    Sci Rep; 2018 Feb; 8(1):2964. PubMed ID: 29445178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diarrhea-predominant irritable bowel syndrome of spleen deficiency and damp excess treated with fire needling therapy with filiform needle and acupoint application therapy: a randomized controlled trial].
    Shi H; Niu Y; Huang Q; Yang ZM; Yang L
    Zhongguo Zhen Jiu; 2021 Sep; 41(9):984-90. PubMed ID: 34491647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial.
    Shin SY; Cha BK; Kim WS; Park JY; Kim JW; Choi CH
    J Neurogastroenterol Motil; 2020 Jan; 26(1):117-127. PubMed ID: 31917916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Parallel-group Study of Digital Gut-directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome.
    Berry SK; Berry R; Recker D; Botbyl J; Pun L; Chey WD
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3152-3159.e2. PubMed ID: 37391055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of acupuncture for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized clinical trial.
    Qi LY; Yang JW; Yan SY; She YF; Hu H; Li Y; Chi LL; Wu BQ; Tu JF; Wang LQ; Liu CZ
    Trials; 2022 Aug; 23(1):711. PubMed ID: 36028847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.